Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLF10 | Q13118 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045742 | 0.83 | KLF10 (0.46) | KLF10MEN1KMT2ANQO2IDO1 | |
| SCHEMBL31085526 | 0.83 | KLF10 (0.44) | KLF10CYP2D6IDO1FFAR4KDM4E | |
| SCHEMBL1014987 | 0.83 | KLF10 (0.44) | KLF10CYP2D6IDO1FFAR4KDM4E | |
| SCHEMBL3174968 | 0.82 | MEN1 (0.44) | KLF10MEN1KMT2AESR1ESR2 | |
| SCHEMBL178283 | 0.82 | ESR1 (0.69) | KLF10MEN1KMT2AESR1ESR2 | |
| SCHEMBL17141554 | 0.80 | MEN1 (0.47) | KLF10MEN1KMT2AESR1ESR2 | |
| SCHEMBL19347174 | 0.80 | PTGDR2 (0.59) | FFAR4 | |
| SCHEMBL2000882 | 0.79 | CES2 (0.50) | KLF10CYP2D6IDO1KIF11 | |
| SCHEMBL1167122 | 0.79 | IDO1 (0.58) | KLF10MEN1KMT2ACYP2D6IDO1 | |
| SCHEMBL5636034 | 0.79 | KLF10 (0.78) | KLF10MEN1KMT2AESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3022202-B1 | AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE | NOVARTIS AG (CH) | 2019-05-15 | — | — | EP | disclosed |
| US-10183025-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2019-01-22 | — | — | US | disclosed |
| US-20180021345-A1 | AUTOTAXIN INHIBITORS | NOVARTIS AG (CH) | 2018-01-25 | — | — | US | disclosed |
| CN-105555783-B | Include the autotaxin inhibitors of heteroaromatic rings benzyl amide ring core | 诺华股份有限公司 | 2017-12-01 | — | — | CN | disclosed |
| US-9763957-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-20160184318-A1 | AUTOTAXIN INHIBITORS | NOVARTIS AG (CH) | 2016-06-30 | — | — | US | disclosed |
| EP-3022202-A1 | AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| CN-105555783-A | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core | NOVARTIS AG | 2016-05-04 | — | — | CN | disclosed |
| WO-2015008230-A1 | AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
| EP-2421834-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| US-20020188011-A1 | Antiviral agents and methods of treating viral infections | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-12-12 | — | — | US | disclosed |
| WO-2002085358-A2 | ANTIVIRAL AGENTS AND METHODS OF TREATING VIRAL INFECTIONS | VION PHARMACEUTICALS, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
| CN-1374967-A | Compounds for the treatment of ischemia | PFIZER PROD INC (US) | 2002-10-16 | — | — | CN | disclosed |
| US-6458816-B1 | ANTICANCER AGENTS | VION PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020119955-A1 | Modified prodrug forms of AP/AMP | NANOTHERAPEUTICS, INC. | 2002-08-29 | — | — | US | disclosed |
| EP-1216257-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2002030424-A1 | MODIFIED PRODRUG FORMS OF AP/AMP | VION PHARMACEUTICALS, INC. (US) | 2002-04-18 | — | — | WO | disclosed |
| WO-2001023399-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| US-5587392-A | THERAPY FOR ESTROGEN DEPENDENT DISEASES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| EP-0684235-A1 | Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188011-A1 | Antiviral agents and methods of treating viral infections | AMPD3, AMPD2, MTAP | KLF10 3653/4885MEN1 4074/4885KMT2A 2374/4885 |
| US-20160184318-A1 | AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, TFPI | KLF10 3282/4885MEN1 1112/4885KMT2A 3346/4885 |
| US-20180021345-A1 | AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, TFPI | KLF10 3282/4885MEN1 1112/4885KMT2A 3346/4885 |
| US-20020119955-A1 | Modified prodrug forms of AP/AMP | AP3B1, AP3D1, AP3M1 | KLF10 4565/4885MEN1 861/4885KMT2A 3616/4885 |
| US-10183025-B2 | Autotaxin inhibitors | ENPP2, SERPINB1, TFPI | KLF10 3282/4885MEN1 1112/4885KMT2A 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.